Brief: Everest Medicines Says First Person Dosed In Global Phase 3 Registration Trial Of Sacituzumab Govitecan-Hziy
26/08/2021 14:41
Aug 26 (Reuters) - Everest Medicines Ltd 1952.HK :
* EVEREST MEDICINES ANNOUNCES FIRST PERSON DOSED IN GLOBAL
PHASE 3
REGISTRATION TRIAL OF SACITUZUMAB GOVITECAN-HZIY IN CHINA FOR
METASTATIC UROTHELIAL CANCER
Source text for Eikon: ID:nPn3jSlQJa
Further company coverage: 1952.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Everest Medicines
See all newsBrief: Everest Medicines Says NMPA Approves Cardamyst (Etripamil) NDA For PSVT In Adults In China
Brief: Everest Medicines Enters Commercialization Collaboration With Hainan Herui Pharmaceutical
Brief: Everest Medicines Says CBC Group Purchases 712,000 Everest Medicines Shares For Hk$19.2 Million From 16 To 17 June
Australia's Dimerix soars on commercialisation deal with Everest Medicines
Brief: Dimerix Ltd Licenses Dmx200 To Everest For China And Asia Region